ARMP vs VRTX
ARMP: Armata is a clinical-stage phage biotech using engineered bacteriophages as a targeted, microbiome-friendly alternative to antibiotics for drug-resistant bacterial infections. VRTX: Vertex is a leader in biotechnology primarily recognized for its dominance in cystic fibrosis therapy and its emerging pipeline of gene-editing treatments and non-opioid pain relief.
Side-by-side fundamentals
| Metric | ARMP | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $5.15 | $478.71 | |
| Market cap as of 2026-08-05 | $172M | $121.5B | |
| P/E as of 2026-08-04 | n/a | 27.85 | |
| PEG as of 2026-08-05 | -0.00 | 2.28 | ARMP lower |
| Net margin as of 2026-08-05 | -5432.8% | +35.0% | VRTX higher |
| Gross margin as of 2026-08-04 | n/a | +86.0% | |
| Operating margin as of 2026-08-05 | -715.6% | +38.0% | VRTX higher |
| ROE as of 2026-08-05 | -120.0% | +23.3% | VRTX higher |
| ROA as of 2026-08-05 | -356.6% | +16.9% | VRTX higher |
| Debt / equity as of 2026-08-05 | 1.38 | 0.01 | VRTX lower |
| Revenue growth (YoY) as of 2026-08-05 | +10.7% | +10.2% | ARMP higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +10.4% | |
| Beta as of 2026-08-05 | 1.39 | 0.48 | |
| 1-year return as of 2026-07-27 close | +115.5% | +1.4% | ARMP higher |
Fundamentals: market data, as of 2026-08-05. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.